Bajpai, R ORCID: https://orcid.org/0000-0002-1227-2703, Muller, SN ORCID: https://orcid.org/0000-0001-6645-5751, Mallen, C ORCID: https://orcid.org/0000-0002-2677-1028, Watson, L, Richette, P, Hider, SL ORCID: https://orcid.org/0000-0002-9958-3909 and Roddy, E ORCID: https://orcid.org/0000-0002-8954-7082 (2021) Onset of comorbidities and flare patterns within pre-existing morbidity clusters in people with gout: 5-year primary care cohort study. Rheumatology.

[img] Text
GOLF-Rheumatology-manuscript-accepted.docx - Accepted Version
Restricted to Repository staff only until 21 March 2022.
Available under License Creative Commons Attribution Non-commercial.

Download (4MB)

Abstract

OBJECTIVE: To investigate the onset of comorbidities and pattern of flares over five years according to baseline comorbidity clusters in people with gout. METHODS: In a prospective primary-care-based cohort study, adults aged ≥18 years with gout, were identified from primary care medical records in 20 general practices across the West Midlands, UK and followed-up over five years. Four clusters of participants have been defined previously according to baseline comorbidity status. The associations of (i) incident comorbidities and (ii) gout flares with baseline cluster membership were estimated using age and sex-adjusted Poisson regression and mixed effects ordinal logistic regression, respectively. RESULTS: The comorbidity with the highest incidence was coronary artery disease (39.2%), followed by hypertension (36.7%), chronic kidney disease stage ≥3 (18.1%), obesity (16.0%), hyperlipidaemia (11.7%), diabetes (8.8%), and cancer (8.4%). There were statistically significant associations observed between cluster membership and incidence of coronary artery disease, hyperlipidaemia, heart failure, and hypertension. In each cluster, nearly one-third of participants reported ≥2 gout flares at each time-point. History of oligo/polyarticular flares (odds ratio [OR]: 2.16; 95% confidence interval [CI]: 1.73-2.70), and obesity (1.66; 1.21-2.25) were associated with increasing flares whereas current use of allopurinol was associated with lower risk (0.42; 0.34-0.53). Cluster membership was not associated with flares. CONCLUSION: Substantial numbers of people in each cluster developed new comorbidities that varies by cluster membership. People also experienced multiple flares over time, but these did not differ between clusters. Clinicians should be vigilant for the development of new comorbidities in people with gout.

Item Type: Article
Additional Information: The final version of this accepted manuscript and all relevant information can be found online at; https://academic.oup.com/rheumatology/advance-article-abstract/doi/10.1093/rheumatology/keab283/6179312
Subjects: R Medicine > R Medicine (General)
R Medicine > RA Public aspects of medicine
R Medicine > RC Internal medicine > RC925 Diseases of the musculoskeletal system
Divisions: Faculty of Medicine and Health Sciences > School of Primary, Community and Social Care
Related URLs:
Depositing User: Symplectic
Date Deposited: 27 Apr 2021 14:14
Last Modified: 29 Apr 2021 14:40
URI: https://eprints.keele.ac.uk/id/eprint/9430

Actions (login required)

View Item View Item